Yuqi Zhang

Yuqi Zhang

Auto-generated profile, based on publicly available information

Yuqi Zhang

Department of Rheumatology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YZYuqi Zhang
Yuqi Zhang
KDKeqian Du
Keqian Du
XFXiaoxue Feng
Xiaoxue Feng
JXJia Xu
Jia Xu
PXPeijun Xu
Peijun Xu
JHJianlin Huang
Jianlin Huang
Purpose: This study aimed to compare the rates of disease remission evaluated using various remission criteria, including Boolean2.0, Boolean1.0, clinical disease activity index (CDAI), simplified disease activity index (SDAI), and disease activity score using 28 joints based on C-reactive protein (DAS28-CRP) in patients with rheumatoid arthritis (RA). Patients and Methods: A cross-sectional observational analysis was performed using data from patients with RA enrolled in a smart system of disease management group (SSDM). The clinical remission rates of RA patients estimated using the DAS28-CRP, CDAI, SDAI, Boolean1.0 and Boolean2.0 criteria were investigated. Variables were compared using the t-test, Mann–Whitney U-test, or chi-squared test. The agreement between Boolean remission and the DAS28-CRP, CDAI, or SDAI definitions of remission was assessed using McNemar’s test with k coefficient of agreement. Results: A total of 5619 patients were included in the analysis. The mean age of the patients was 56.33 (± 13.01) years, with the majority being female (4491, 79.9%). The rates of remission, as assessed by Boolean2.0, Boolean1.0, DAS28-CRP, CDAI, and SDAI, were 16.6%, 9.7%, 35.2%, 9.1%, and 9.4%, respectively. Comparison with Boolean1.0 criteria revealed higher concordance between Boolean2.0 and DAS28-CRP remission and lower concordance with CDAI and SDAI, regardless of whether the analysis was conducted on the entire population or subgroups based on gender, age or disease duration. Additionally, the administration of different medications may have influenced the rate of Boolean2.0 remission. Conclusion: This study demonstrated a higher concordance between Boolean2.0 criteria and DAS28-CRP remission and a lower concordance with CDAI and SDAI when compared with Boolean1.0 remission criteria.

25 April 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
YZYuqi Zhang
Yuqi Zhang
PXPeijun Xu
Peijun Xu
JHJianlin Huang
Jianlin Huang
ZHZaiying Hu
Zaiying Hu

21 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YZYuqi Zhang
Yuqi Zhang
KDKeqian Du
Keqian Du
BWBin Wu
Bin Wu
YWYongfu Wang
Yongfu Wang
HWHua Wei
Hua Wei
JHJianlin Huang
Jianlin Huang
Rheumatoid arthritis (RA) is a chronic inflammatory disease requiring early diagnosis and treatment to achieve sustained clinical remission. Achieving a state of remission is associated with favorable outcomes. However, predictive factors for Boolean2.0 remission in RA patients are limited. This retrospective observational study analyzed data from RA patients enrolled in a smart system of disease management group (SSDM) between January 2014 and December 2023. Demographic and clinical characteristics were compared between patients who achieved Boolean2.0 remission and those who did not. Univariate and multivariate logistic regression analyses were performed to identify predictive factors associated with Boolean2.0 remission. Among 5004 patients enrolled for analysis, 541 (10.8%) achieved Boolean2.0 remission. The median (IQR) age at diagnosis of the patients was 51.00 (42.00, 60.00) years, with the majority being female (3978, 79.5%). The median (IQR) disease duration was 26.00 (3.00, 89.00) months. Logistic regression analyses revealed that the likelihood of achieving Boolean2.0 remission was greater in patients who were younger (P = 0.008), had a shorter disease duration (P < 0.001), a lower number of tender joints (P < 0.001), and were prescribed methotrexate (P = 0.012) and leflunomide (P = 0.001). Younger age, shorter disease duration, lower count of tender joints, and treatment with methotrexate and leflunomide were associated with increased likelihood of achieving Boolean2.0 remission. These findings can guide clinicians in identifying high-risk patients and optimizing treatment strategies.